Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis

Cancer Research

Volumn 72, Issue 12, 2012, Pages 3080-3090

  Lahlou, Hicham ^a   Müller, Thomas ^c   Sanguin Gendreau, Virginie ^a   Birchmeier, Carmen ^c   Muller, William J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST DISEASE; BREAST TUMOR; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENE LOSS; GENETIC ASSOCIATION; HETEROZYGOSITY; HOMOZYGOSITY; LACTATION DISORDER; MAMMARY GLAND; METASTASIS; MMMARY EPITHELIAL OUTGROWTH; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE ERBB2; ORGANOGENESIS; PRIORITY JOURNAL; SEVERE MAMMARY DUCTAL OUTGROWTH DEFECT; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; LACTATION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84862532797     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3513     Document Type: Article

References (45)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54. (Pubitemid 40637826)
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev 2001;2:127-37. (Pubitemid 33674041)
3. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65. (Pubitemid 36342255)
4. Andrechek ER, White D, Muller WJ. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 2005;24:932-7. (Pubitemid 40216100)
5. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
6. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-7. (Pubitemid 47258458)
7. Sithanandam G, Smith GT, Fields JR, Fornwald LW, Anderson LM. Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. Am J Respir Cell Mol Biol 2005;33:490-9. (Pubitemid 41572693)
8. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008;13:215-23.
9. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87. (Pubitemid 47530601)
10. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001;6:393-406.
11. Czerwenka KF, Manavi M, Hosmann J, Jelincic D, Pischinger KI, Battistutti WB, et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue. Cancer Detect Prev 2001;25:268-79.
12. Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998;78:1385-90. (Pubitemid 28495255)
13. Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994;25:247-52.
14. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR, et al. Clinical and prognostic signi fi cance of the expression of the c-erbB- 2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 1997;17:1319-30.
15. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64. (Pubitemid 29179172)
16. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647-56. (Pubitemid 30200966)
17. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933-8. (Pubitemid 36899201)
18. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97. (Pubitemid 46652484)
19. Cook RS, Garrett JT, Sanchez V, Stanford JC, Young C, Chakrabarty A, et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res 2011;71:3941-51.
20. Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997;17:5410-25. (Pubitemid 27357639)
21. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994;13:2831-41.
22. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8. (Pubitemid 24160762)
23. Stern DF. ErbBs in mammary development. Exp Cell Res 2003;284:89-98. (Pubitemid 36331968)
24. Troyer KL, Lee DC. Regulation of mousemammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 2001;6:7-21. (Pubitemid 33640643)
25. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-8.
26. Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 1999;18:3481-90. (Pubitemid 29317343)
27. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci U S A 2004;101:17138-43. (Pubitemid 39627787)
28. Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, et al. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res 2008;10:R96.
29. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1:20050008.
30. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 2007;104:20302-7.
31. Kong M, Mounier C, Dumas V, Posner BI. Epidermal growth factor-induced DNA synthesis. key role for Src phosphorylation of the docking protein Gab2. J Biol Chem 2003;278:5837-44. (Pubitemid 36800830)
32. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995;269:230-4.
33. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
34. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-45. (Pubitemid 46328463)
35. Gillgrass A, Cardiff RD, Sharan N, Kannan S, Muller WJ. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene 2003;22:9151-5. (Pubitemid 38067990)
36. Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 1997;389:725-30. (Pubitemid 27458958)
37. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010;70:1204-14.
38. Holzenberger M, Leneuve P, Hamard G, Ducos B, Perin L, Binoux M, et al. A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit. Endocrinology 2000;141:2557-66. (Pubitemid 32269076)
39. Darcy KM, Zangani D, Wohlhueter AL, Huang RY, Vaughan MM, Russell JA, et al. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J Histochem Cytochem 2000;48:63-80. (Pubitemid 30053567)
40. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N, et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2006;12:114- 21.
41. Ursini-Siegel J, Hardy WR, Zheng Y, Ling C, Zuo D, Zhang C, et al. The ShcA SH2 domain engages a 14-3-3/PI30 K signaling complex and promotes breast cancer cell survival. Oncogene. 2012 Jan 30. [Epub ahead of print].
42. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
43. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Breast Cancer Special Feature: feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012;109:2718-23.
44. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41. (Pubitemid 46160912)
45. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37. (Pubitemid 41039113)